Pulmonary delivery of anti-cancer agents

Advanced Drug Formulation Design to Optimize Therapeutic Outcomes

Volumn , Issue , 2007, Pages 81-112

  Smyth, Hugh D C ^a   Saleem, Imran ^a   Donovan, Martin ^a   Verschraegen, Claire F ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84978718021     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (130)

1. Pirozynski M. 100 years of lung cancer. Respir Med 2006; 100(12):2073–84.
2. Yang QE, Fong SE, Li K, Gonda MA, Tobin GJ. Ex vivo expanded murine bone marrow cells with a multiple cytokine cocktail retain long-term hematopoietic reconstitution potentials. Med Sci Monit 2005; 11(6): BR154–61.
3. Bonfill X, Serra C, Sacristan M, Nogue M, Losa F, Montesinos J. Second-line chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2002(2):CD002804.
4. Agra Y, Pelayo M, Sacristan M, Sacristan A, Serra C, Bonfill X. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev 2003(4):CD001990.
5. Carney DN, Hansen HH. Non-small-cell lung cancer—stalemate or progress? N Engl J Med 2000; 343(17):1261–2.
6. Carney DN. Lung cancer—time to move on from chemotherapy. N Engl J Med 2002; 346(2):126–8.
7. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6(8):583–92.
8. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 2005; 11(24 Pt 1):8782–8.
9. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005; 5(7):516–25.
10. Davis AJ, Tannock IF. Tumor physiology and resistance to chemotherapy: repopulation and drug penetration. Cancer Treat Res 2002; 112:1–26.
11. Smyth HD, Leach CL. Alternative propellant aerosol delivery systems. Crit Rev Ther Drug Carrier Syst 2005; 22(6):493–534.
12. Smyth HDC, Garmise R, Cooney D, Garcia-Contreras L, Jones LD, Hickey AJ. Medical and Pharmaceutical Aerosols. In: Ruzer LH, N.H., ed. Aerosols Handbook: Measurement, Dosimetry, and Health Effects. New York: CRC Press; 2004.
13. Smyth HD. Propellant-driven metered-dose inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2005; 2(1):53–74.
14. Smyth HDC, Garcia-Contreras L. Dry-powder or liquid spray systems for inhaled delivery of peptides and proteins. Am J Drug Deliv 2005; 3(1): 29–45.
15. Smyth HDC, Hickey AJ. Carriers in drug powder delivery: implications for inhalation system design. Am J Drug Deliv 2005; 3(2):117–32.
16. Blackhall FH, Shepherd FA, Albain KS. Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer: a realistic goal? Treat Respir Med 2005; 4(2):71–84.
17. Bahl A, Sharma DN, Julka PK, Rath GK. Chemotherapy related toxicity in locally advanced non-small cell lung cancer. J Cancer Res Ther 2006; 2(1): 14–16.
18. Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984; 2:498–504.
19. Dedrick RL. Arterial drug infusion: Pharmacokinetic problems and pitfalls. J Natl Cancer Inst 1988; 80:84–89.
20. Sharma S, White DI, A. R., Placke ME, Vail DM, Kris MG. Development of inhalational agents for oncologic use. J Clin Oncol 2001; 19(6):1839–47.
21. Tomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; 9: 539–49.
22. Less JL, Skalak EM, Sevick EM, Jain RK. Micrvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 1991; 51:265–73.
23. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58:1408–16.
24. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 2000; 60:4324–7.
25. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure— an obstacle in cancer therapy. Nature Rev Cancer 2004; 4:806–13.
26. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000; 60:2497–503.
27. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 2006; 17(4):543–52.
28. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006; 24(7):1057–63.
29. Brade AM, Tannock IF. Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure? J Clin Oncol 2006; 24(7):1020–2.
30. Wu L, Tannock IF. Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil. Cancer Res 2003; 63(9):2134–8.
31. Maciejewski B, Majewski S. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol 1991; 21(3):163–70.
32. Nadithe V, Rahamatalla M, Finlay WH, Mercer JR, Samuel J. Evaluation of nose-only aerosol inhalation chamber and comparison of experimental results with mathematical simulation of aerosol deposition in mouse lungs. J Pharm Sci 2003; 92(5):1066–76.
33. Shevchenko IT, Resnik GE. Inhalation of chemical substances and oxygen in radiotherapy of bronchial cancer. Neoplasma 1968; 15(4):419–26.
34. Sugawa IT. A study on transairway carcinostatic dose for lung metastases. Ochanomizu Med J 1970; 18(3):103–14.
35. Tatsumura T, Yamamoto K, Murakami A, Tsuda M, Sugiyama S. [New chemotherapeutic method for the treatment of tracheal and bronchial cancers–nebulization chemotherapy]. Gan No Rinsho 1983; 29(7): 765–70.
36. Tatsumura T, Koyama S, Tsujimoto M, Kitagawa M, Kagamimori S. Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br J Cancer 1993; 68 (6):1146–9.
37. Cusumano CL, Jernigan JA, Waldman RH. Aerosolized BCG (Tice strain) treatment of bronchogenic carcinoma: phase I study. J Natl Cancer Inst 1975; 55(2):275–9.
38. Juliano RL, McCullough HN. Controlled delivery of an antitumor drug: localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system. J Pharmacol Exp Ther 1980; 214(2):381–7.
39. Batkin S, Tabrah FL. Ethanol vapour modulation of Lewis lung carcinoma, a murine pulmonary tumour. J Cancer Res Clin Oncol 1990; 116(2):187–9.
40. van Zandwijk N, Jassem E, Dubbelmann R, Braat MC, Rumke P. Aerosol application of interferon-alpha in the treatment of bronchioloalveolar carcinoma. Eur J Cancer 1990; 26(6):738–40.
41. Eisenberg BL, Taylor DD, Weese JL. Aerosolized gamma-interferon and lipopolysaccharide enhances cytotoxicity of murine pulmonary alveolar macrophages. J Immunother 1991; 10(1):51–6.
42. Kessler R, Dumont S, Bartholeyns J, Weitzenblum E, Poindron P. Antitumoral potential of aerosolized interferon-gamma in mice bearing lung metastases. Am J Respir Cell Mol Biol 1994; 10(2):202–6.
43. Johnston MR, Minchen RF, Dawson CA. Lung perfusion with chemotherapy in patients with unresectable metastatic sarcoma to the lung or diffuse bronchioloalveolar carcinoma. J Thorac Cardiovasc Surg 1995; 110: 368–73.
44. Ng B, Hochwald SN, Burt ME. Isolated lung perfusion with doxorubicin reduces cardiac and host toxicities associated with systemic administration. Ann Thorac Surg 1996; 61:969–72.
45. Lorenz J, Wilhelm K, Kessler M, et al. Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects. Clin Cancer Res 1996; 2(7):1115–22.
46. Khanna C, Hasz DE, Klausner JS, Anderson PM. Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: canine studies. Clin Cancer Res 1996; 2(4):721–34.
47. Goldbach P, Dumont S, Kessler R, Poindron P, Stamm A. In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-gamma and muramyl tripeptide. Am J Physiol 1996; 270(3 Pt 1):L429–34.
48. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Steele VE, Kelloff GJ. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res 1997; 57(24):5489–92.
49. Wattenberg LW, Wiedmann TS, Estensen RD, et al. Chemoprevention of pul monary carci nogenesi s by bri ef exposures to aerosol i zed budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis 2000; 21(2): 179–82.
50. Estensen RD, Jordan MM, Wiedmann TS, Galbraith AR, Steele VE, Wattenberg LW. Effect of chemopreventive agents on separate stages of progression of benzo[alpha]pyrene induced lung tumors in A/J mice. Carcinogenesis 2004; 25(2):197–201.
51. Khanna C, Anderson PM, Hasz DE, Katsanis E, Neville M, Klausner JS. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 1997; 79(7):1409–21.
52. Trigg RL, Zutshi A. Absorption, distribution and elimination of 14C-labeled doxorubicin co-administered with 99mTc by inhalation to dogs. Battelle Data File; 1999.
53. Knight V, Koshkina NV, Waldrep JC, Giovanella BC, Gilbert BE. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol 1999; 44(3):177–86.
54. Knight V, Kleinerman ES, Waldrep JC, Giovanella BC, Gilbert BE, Koshkina NV. 9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Ann NY Acad Sci 2000; 922:151–63.
55. Knight V, Koshkina N, Waldrep C, Giovanella BC, Kleinerman E, Gilbert B. Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice. Trans Am Clin Climatol Assoc 2000; 111:135–45.
56. Koshkina NV, Kleinerman ES, Waidrep C, et al. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 2000; 6(7):2876–80.
57. Hershey AE, Kurzman ID, Forrest LJ, et al. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res 1999; 5(9): 2653–9.
58. Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 1999; 5 (9):2316–23.
59. Koshkina NV, Gilbert BE, Waldrep JC, Seryshev A, Knight V. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother Pharmacol 1999; 44(3): 187–92.
60. Verschraegen CF, Gilbert BE, Huaringa AJ, et al. Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs. Ann NY Acad Sci 2000; 922: 352–4.
61. Verschraegen CF, Gilbert BE, Loyer E, et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 2004; 10(7): 2319–26.
62. Brooks AD, Tong W, Benedetti F, Kaneda Y, Miller V, Warrell RP, Jr. Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery. Cancer Chemother Pharmacol 2000; 46(4):313–8.
63. Skubitz KM, Anderson PM. Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial. Anticancer Drugs 2000; 11(7): 555–63.
64. Gautam A, Densmore CL, Waldrep JC. Inhibition of experimental lung metastasis by aerosol delivery of PEI-p53 complexes. Mol Ther 2000; 2(4): 318–23.
65. Densmore CL, Kleinerman ES, Gautam A, et al. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther 2001; 8(9):619–27.
66. Gautam A, Waldrep JC, Densmore CL, et al. Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin. Gene Ther 2002; 9(5):353–7.
67. Gautam A, Densmore CL, Melton S, Golunski E, Waldrep JC. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther 2002; 9(1):28–36.
68. Wang DL, Marko M, Dahl AR, et al. Topical delivery of 13-cis-retinoic acid by inhalation up-regulates expression of rodent lung but not liver retinoic acid receptors. Clin Cancer Res 2000; 6(9):3636–45.
69. Gautam A, Densmore CL, Xu B, Waldrep JC. Enhanced gene expression in mouse lung after PEI-DNA aerosol delivery. Mol Ther 2000; 2(1):63–70.
70. Zou Y, Zong G, Ling YH, Perez-Soler R. Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer. Cancer Gene Ther 2000; 7(5):683–96.
71. Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 2001; 7(10): 3258–62.
72. 2-enriched air: pharmacokinetic studies. Cancer Chemother Pharmacol 2001; 47(5):451–6.
73. Lee HY, Suh YA, Lee JI, et al. Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer. Clin Cancer Res 2002; 8(9):2970–5.
74. Kohlhaufl M, Haussinger K, Stanzel F, et al. Inhalation of aerosolized vitamin a: reversibility of metaplasia and dysplasia of human respiratory epithelia—a prospective pilot study. Eur J Med Res 2002; 7(2):72–8.
75. Shaik MS, Haynes A, McSween J, Ikediobi O, Kanikkannan N, Singh M. Inhalation delivery of anticancer agents via HFA-based metered dose inhaler using methotrexate as a model drug. J Aerosol Med 2002; 15(3):261–70.
76. Haynes A, Shaik MS, Chatterjee A, Singh M. Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line. Pharm Res 2003; 20(9):1485–95.
77. Jia SF, Worth LL, Densmore CL, Xu B, Duan X, Kleinerman ES. Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin Cancer Res 2003; 9(9):3462–8.
78. Wang Z, Chen HT, Roa W, Finlay W. Farnesol for aerosol inhalation: nebulization and activity against human lung cancer cells. J Pharm Pharm Sci 2003; 6(1):95–100.
79. Lawson KA, Anderson K, Menchaca M, et al. Novel vitamin E analogue decreases syngeneic mouse mammary tumor burden and reduces lung metastasis. Mol Cancer Ther 2003; 2(5):437–44.
80. Lawson KA, Anderson K, Simmons-Menchaca M, et al. Comparison of vitamin E derivatives alpha-TEA and VES in reduction of mouse mammary tumor burden and metastasis. Exp Biol Med (Maywood) 2004; 229(9):954–63.
81. Zhang S, Lawson KA, Simmons-Menchaca M, Sun L, Sanders BG, Kline K. Vitamin E analog alpha-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice. Breast Cancer Res Treat 2004; 87(2):111–21.
82. Li X, Fu GF, Fan YR, et al. Potent inhibition of angiogenesis and liver tumor growth by administration of an aerosol containing a transferrin-liposome-endostatin complex. World J Gastroenterol 2003; 9(2):262–6.
83. Witschi H, Espiritu I, Ly M, Uyeminami D, Morin D, Raabe OG. Chemoprevention of tobacco smoke-induced lung tumors by inhalation of an epigallocatechin gallate (EGCG) aerosol: a pilot study. Inhal Toxicol 2004; 16(11–12):763–70.
84. Liao X, Liang W, Wiedmann T, Wattenberg L, Dahl A. Lung distribution of the chemopreventive agent difluoromethylornithine (DFMO) following oral and inhalation delivery. Exp Lung Res 2004; 30(8):755–69.
85. Tian Y, Klegerman ME, Hickey AJ. Evaluation of microparticles containing doxorubicin suitable for aerosol delivery to the lungs. PDA J Pharm Sci Technol 2004; 58(5):266–75.
86. Zou Y, Fu H, Ghosh S, Farquhar D, Klostergaard J. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin Cancer Res 2004; 10(21):7382–91.
87. Kim HW, Park IK, Cho CS, et al. Aerosol delivery of glucosylated polyethylenimine/phosphatase and tensin homologue deleted on chromosome 10 complex suppresses Akt downstream pathways in the lung of K-ras null mice. Cancer Res 2004; 64(21):7971–6.
88. Lawson KA, Anderson K, Snyder RM, et al. Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis. Cancer Chemother Pharmacol 2004; 54(5):421–31.
89. Koshkina NV, Golunski E, Roberts LE, Gilbert BE, Knight V. Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. J Aerosol Med 2004; 17(1):7–14.
90. Wattenberg LW, Wiedmann TS, Estensen RD. Chemoprevention of cancer of the upper respiratory tract of the Syrian golden hamster by aerosol administration of difluoromethylornithine and 5-fluorouracil. Cancer Res 2004; 64(7):2347–9.
91. Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer 2005; 116(3):458–63.
92. Haynes A, Shaik MS, Chatterjee A, Singh M. Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer. Pharm Res 2005; 22(3): 427–39.
93. Gagnadoux F, Pape AL, Lemarie E, et al. Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur Respir J 2005; 26(4): 657–61.
94. Gagnadoux F, Leblond V, Vecellio L, et al. Gemcitabine aerosol: in vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons. Cancer Chemother Pharmacol 2006; 58(2):237–44.
95. Gagnadoux F, LePape A, Urban T, et al. Safety of pulmonary administration of gemcitabine in rats. J Aerosol Med 2005; 18(2):198–206.
96. Azarmi S, Tao X, Chen H, et al. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm 2006; 319 (1–2):155–61.
97. Hitzman CJ, Wattenberg LW, Wiedmann TS. Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. J Pharm Sci 2006; 95(6):1196–211.
98. Hitzman CJ, Elmquist WF, Wiedmann TS. Development of a respirable, sustained release microcarrier for 5-fluorouracil II: In vitro and in vivo optimization of lipid coated nanoparticles. J Pharm Sci 2006; 95 (5):1127–43.
99. Hitzman CJ, Elmquist WF, Wattenberg LW, Wiedmann TS. Development of a respirable, sustained release microcarrier for 5-fluorouracil I: In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J Pharm Sci 2006; 95(5):1114–26.
100. Glaberman U, Rabinowitz I, Verschraegen CF. Alternative administration of camptothecin analogues. Expert Opin Drug Deliv 2005; 2(2):323–33.
101. Liebes L, Potmesil M, Kim T, et al. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Clin Cancer Res 1998; 4(3):545–57.
102. Nabiev I, Fleury F, Kudelina I, et al. Spectroscopic and biochemical characterisation of self-aggregates formed by antitumor drugs of the camptothecin family: their possible role in the unique mode of drug action. Biochem Pharmacol 1998; 55(8):1163–74.
103. Gabr A, Kuin A, Aalders M, El-Gawly H, Smets LA. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. Cancer Res 1997; 57(21):4811–6.
104. Verschraegen CF, Natelson EA, Giovanella BC, et al. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 1998; 9(1):36–44.
105. Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989; 32(3):715–20.
106. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972; 56(1):95–101.
107. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I–targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246(4933): 1046–8.
108. Herben VM, ten BokkelHuinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996; 31(2):85–102.
109. Natelson EA, Giovanella BC, Verschraegen CF, et al. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann N Y Acad Sci 1996; 803:224–30.
110. Gilbert BE, Wyde PR, Lopez-Berestein G, Wilson SZ. Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice. Antimicrob Agents Chemother 1994; 38(2):356–9.
111. Gilbert BE, Wyde PR, Wilson SZ. Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice. Antimicrob Agents Chemother 1992; 36(7):1466–71.
112. Gilbert B, Black MB, Waldrep JC, Bennick J, Montgomery C, Knight CM. Cyclosporin A liposome aerosol:lack of acute toxicity in rats with a high incidence of underlying pneumonitis. Inhal Toxicol 1997; 9:717–30.
113. Waldrep JC, Gilbert BE, Knight CM, et al. Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Tolerance and safety. Chest 1997; 111(2):316–23.
114. Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol 1996; 42(6):697–705.
115. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004; 1(4):338–44.
116. Sakagami M, Byron PR, Venitz J, Rypacek F. Solute disposition in the rat lung in vivo and in vitro: determining regional absorption kinetics in the presence of mucociliary escalator. J Pharm Sci 2002; 91(2):594–604.
117. Smyth HDC, Saleem I, Donovan MJ. Emerging carriers for pulmonary drug delivery, cover story. AAPS News Magazine 2006; 9(8):12–15.
118. Smyth HDC, Saleem I, Donovan M. Emerging carriers for pulmonary drug delivery. Am Assoc Pharm Scie News Mag 2006; 9 (8):Cover Story.
119. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004; 1(4):338–44.
120. Gorin AB, Stewart PA. Differential permeability of endothelial and epithelial barriers to albumin flux. J Appl Physiol 1979; 47(6):1315–24.
121. Wangensteen OD, Schneider LA, Fahrenkrug SC, Brottman GM, Maynard RC. Tracheal epithelial permeability to nonelectrolytes: species differences. J Appl Physiol 1993; 75(2):1009–18.
122. Boucher RC, Stutts MJ, Gatzy JT. Regional differences in bioelectric properties and ion flow in excised canine airways. J Appl Physiol 1981; 51 (3):706–14.
123. Byron PR. Determinants of drug and polypeptide bioavailability from aerosols delivered to the lung. Adv Drug Deliev Rev 1990; 5:107–32.
124. Enna SJ, Schanker LS. Absorption of drugs from the rat lung. Am J Physiol 1972; 223:1227–31.
125. Miller BJ, Rosenbaum AS. The vascular supply to metastatic tumors of the lung. Surg Gynecol Obstet 1967; 125:1009–12.
126. Milne EN, Noonan CD, Margulis AR, Stoughton JA. Vascular supply of pulmonary metastases: Experimental study in rats. Invest Radiol 1969; 4: 215–29.
127. Fontanini G, Calcinai A, Boldrini L, et al. Modulation of neoangiogenesis in bronchial preneoplastic lesions. Oncol Rep 1999; 6:813–17.
128. Keith RL, Miller YE, Gemmill RM, et al. Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin Cancer Res 2000; 6: 1616–25.
129. Kleinstreuer C, Zhang Z. Targeted drug aerosol deposition analysis for a four-generation lung airway model with hemispherical tumors. J Biomech Eng 2003; 125(2):197–206.
130. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346(2):92–8.